You are here: Industry Insights > Wuxi Biologics

News List

WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases En-CPhI.CN
January 09, 2020
WuXi Biologics announced the signing of a strategic collaboration agreement enabling Almirall to leverage the proprietary WuXiBody™ platform to develop bispecific antibodies for dermatological diseases.
WuXi Biologics Congratulates Tychan on Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers En-CPhI.CN
November 19, 2019
WuXi Biologics congratulates its partner Tychan on successful completion of the Phase 1A/1B safety and efficacy trials in Singapore for TY014, a first-in-class monoclonal antibody candidate treatment for Yellow Fever (YF).
WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing En-CPhI.cn
June 24, 2019
WuXi Biologics development and manufacturing, announced that it planned to expand the new state-of-the-art integrated biologics conjugation solution center to include commercial manufacturing in Wuxi city, China.
WuXi Biologics signs vaccine manufacturing contract biospectrumasia
May 21, 2019
WuXi Vaccines is a joint venture company to be established between WuXi Biologics and Shanghai based Hile Bio-Technology.
WuXi Biologics Commenced Construction of a 48,000 L Integrated Manufacturing Center for Innovative Biologics in Chengdu En-CPhI.cn
May 17, 2019
The largest manufacturing center for biologics in Southwest China
WuXi Biologics Successfully Completed First FDA Routine GMP Inspection En-CPhI.cn
April 17, 2019
WuXi Biologics announced that its Drug Substance (DS) and Drug Product (DP) manufacturing facilities at Wuxi city successfully completed a seven-day FDA surveillance inspection by three inspectors for the production of Trogarzo™...
WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership en-cphi.cn
April 09, 2019
WuXi Biologics and NBE-Therapeutics (NBE) announced a comprehensive development and manufacturing partnership for NBE's first ADC lead product NBE-002 (anti-ROR1). NBE-002 is a best-in-class immune-stimulatory ADC (iADC) treatment...
WuXi Biologics wins recognition for bioprocessing capabilities biospectrumasia
March 26, 2019
WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery……
WuXi Biologics gets EMA GMP Certificates for Trogarzo biospectrumasia
March 20, 2019
The certification further endorses WuXi Biologics' premier-quality systems and solid reputation as a leading global biomanufacturing player.
WuXi Biologics to be the first biologics company in China approved by both the U.S. FDA and EMA en-cphi.cn
March 20, 2019
WuXi Biologics to be the first biologics company in China approved by both the U.S. FDA and EMA

Previous page 1 2 3 4 5 6 7 8 9 10 Next page